Literature DB >> 16123764

Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.

R Grant Steen1, Robert M Hamer, Jeffrey A Lieberman.   

Abstract

A systematic review of the literature identified 64 published English-language papers that used proton (1H) magnetic resonance spectroscopy to measure N-acetylaspartate (NAA) concurrently in healthy controls and in patients with a diagnosis of schizophrenia (SZ). A total of 1209 controls and 1256 patients have been evaluated, with 88% of studies carried out at 1.5 T field strength, and 77% of studies focused on patients with chronic SZ. There is consistent evidence that NAA is reduced in a broad range of tissues in the SZ brain. Broad consensus (> or =10 studies) is emerging that NAA levels are reduced > or =5% in hippocampus and in both cortical gray matter (GM) and white matter (WM) of the frontal lobe. There is no evidence to support a hypothesis that relative NAA levels are reduced to a different degree in frontal lobe GM and WM, nor is there robust evidence of a difference in NAA levels between patients with first-episode and chronic SZ. Study reliability may be a problem, as most studies appear to be underpowered. With simple assumptions about the inherent difference in NAA levels between patients and controls, it can be calculated that a minimum sample size of approximately 39 patients and 39 controls is required for acceptable statistical power. Only three of 64 studies included enough subjects to have 80% power to detect a 10% NAA reduction in patients, and no studies were adequately powered to detect a 5% NAA reduction with 80% power.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123764     DOI: 10.1038/sj.npp.1300850

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  98 in total

Review 1.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

2.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

3.  Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

Authors:  Juan R Bustillo; Hongji Chen; Charles Gasparovic; Paul Mullins; Arvind Caprihan; Clifford Qualls; William Apfeldorf; John Lauriello; Stefan Posse
Journal:  Biol Psychiatry       Date:  2010-10-20       Impact factor: 13.382

Review 4.  Recent advances in magnetic resonance neurospectroscopy.

Authors:  Yael Rosen; Robert E Lenkinski
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 5.  Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.

Authors:  Stephen R Dager; Neva M Corrigan; Todd L Richards; Stefan Posse
Journal:  Top Magn Reson Imaging       Date:  2008-04

Review 6.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

7.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

Review 8.  A review of MR spectroscopy studies of pediatric bipolar disorder.

Authors:  D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

Review 9.  Age, plasticity, and homeostasis in childhood brain disorders.

Authors:  Maureen Dennis; Brenda J Spiegler; Jenifer J Juranek; Erin D Bigler; O Carter Snead; Jack M Fletcher
Journal:  Neurosci Biobehav Rev       Date:  2013-10-03       Impact factor: 8.989

10.  Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study.

Authors:  M I Atagün; E M Şıkoğlu; S S Can; G Karakaş-Uğurlu; S Ulusoy-Kaymak; A Çayköylü; O Algın; M L Phillips; C M Moore; D Öngür
Journal:  Schizophr Res       Date:  2014-12-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.